Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PYNG Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Stang who wrote (4112)	7/8/1999 6:46:00 PM
From: AriKirA	Read Replies (2) \| Respond to of 8117

Pyng Technologies Corp - Pyng finalizes production design features Pyng Technologies Corp PYT Shares issued 9,788,905 1999-07-06 close $1.31 Thursday Jul 8 1999 Mr. Michael Jacobs reports Pyng Medical Corp. has now finalized the production design features for the F.A.S.T.1 Intraosseous Infusion system. Recently Pyng announced the successful completion of its field trials (Stockwatch April 12, 1999). The speeds of use, success rates and user acceptance in those trials were excellent. One objective of the trials was to let users suggest further improvements to the F.A.S.T.1 system. Many users offered suggestions and comments, all of which were considered, and some adopted, in an improved new design. Based on extensive feedback of experience at the early-adopter and field trial sites, plus engineering and ergonomic expertise, the production design retains or improves on the speed and effectiveness of the best preproduction prototypes. The final preproduction model achieved a success rate of 95 per cent, Pyng's original target. New and improved features of the F.A.S.T.1 include even better ergonomics, a higher level of operator safety, and simplified operating procedures. Ergonomic improvements include refinement of the system's user interface to accommodate a wider range of user ability and skill levels, and a simplified operating procedure. Operator safety has been enhanced by significantly improving the ergonomics of contaminated sharp protection. An easier and simpler method of removing the F.A.S.T.1 infusion tube after treatment will eliminate the need for training of the person removing the system, and will reduce its manufacturing cost, and improve the speed and comfort of the removal process. For reasons of retaining competitive advantage, Pyng will not at this time be releasing details of these new improvements. They will be made public at the beginning of the product launch marketing campaign. Currently the Pyng team is implementing these design features in the detailed engineering of the production model. In other news, Gerry Lenoski and Pyng Medical Corp. mutually agree that Mr. Lenoski will no longer be working for Pyng as manager of corporate communications. (c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com